MedWatch

Bavarian-CEO: operational improvements will continue

Even though profitability of production has been significantly improved in Bavarian Nordic, the company will still become more efficient, says the CEO, who also explains why.

Foto: PR, Bavarian Nordic

A more efficient production of the small pox vaccine Imvamune has enabled the Danish company Bavarian Nordic to supply more vaccines to US authorities than expected. The company has now enhanced expectations for 2012.

But in spite of the improvements leading to upgraded expectations, the company still needs to work on its profitability, CEO Anders Hedegaard tells Medwatch:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier